Dr. Mardi Gomberg-Maitland, associate professor of medicine and director of the pulmonary hypertension program at The University of Chicago Medicine, discusses PAH therapeutic trials, new drugs targeting known pathways and new delivery systems and resurgence of interventional methods.  Dr. Gomberg-Maitland also examines risk assessment, biomarkers and pharmacogenomics.